Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorigerlimab in Pancreatic Adenocarcinoma and HRD
NCT07565155Phase 2Not yet recruiting
- Sponsor
- University of Miami
- Start
- Jan 2027
- Primary completion
- Jan 2032
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lorigerlimab in pancreatic adenocarcinoma (PDAC), sponsored by University of Miami. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
lorigerlimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07565155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565155.